Positions

Overview

  • Dr. Gabrielle Rocque is an Assistant Professor of Medicine in the Divisions of Hematology & Oncology and Gerontology, Geriatrics, & Palliative Care at the University of Alabama at Birmingham (UAB). She completed her undergraduate degree, medical doctorate, Internal Medicine residency, and fellowship in Hematology & Oncology at the University of Wisconsin- Madison. She also completed a Masters of Science in Public Health from UAB. She currently practices as a medical oncologist, specializing in the care of women with breast cancer. Dr. Rocque’s research interests include improving the quality of healthcare delivery for cancer patients with an emphasis on shared decision-making, payment reform, and provision of supportive care services to patients. She served as Medical Director a successful 2012 Center for Medicare and Medicaid Innovation Award, which focused on improving health and healthcare costs by implementing a lay navigator workforce to support cancer patients across from diagnosis through survivorship and end-of-life. She also received an American Cancer Society Mentored Research Scholar Grant to develop treatment plans aimed to enhance shared decision making for patients with metastatic breast cancer. She is active within UAB’s payment reform initiatives, and serves as a member of UAB’s Oncology Care Model Steering Committee. Dr. Rocque has a strong interest in the interface between community oncology practices and academia. She is a former chair of the American Society of Clinical Oncology (ASCO) Measures Task Force and is the chair of the ASCO Quality of Care Committee.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.Cancer.  124:4231-4240. 2018
    2018 Engaging Multidisciplinary Stakeholders to Drive Shared Decision-Making in Oncology.J Palliat Care.  825859718810723. 2018
    2018 Lay navigation across the cancer continuum for older cancer survivors: Equally beneficial for Black and White survivors?Journal of Geriatric Oncology2018
    2018 Choosing Wisely at the End of Life: Use of Shorter Courses of Palliative Radiation Therapy for Bone Metastasis.International Journal of Radiation Oncology - Biology - Physics.  102:320-324. 2018
    2018 Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.Journal of the National Comprehensive Cancer Network.  16:1084-1091. 2018
    2018 Factors Associated with Family Caregivers' Confidence in Future Surrogate Decision Making for Persons with Cancer.Journal of Palliative Medicine2018
    2018 Impact of Guideline-Discordant Treatment on Cost and Health Care Utilization in Older Adults with Early-Stage Breast Cancer.Oncologist2018
    2018 Hospice care, cancer-directed therapy, and Medicare expenditures among older patients dying with malignant brain tumors.Neuro-Oncology.  20:986-993. 2018
    2018 Adapting an Early Palliative Care Intervention to Family Caregivers of Persons With Advanced Cancer in the Rural Deep South: A Qualitative Formative Evaluation.Journal of Pain and Symptom Management.  55:1519-1530. 2018
    2018 Where Are the Opportunities for Reducing Health Care Spending Within Alternative Payment Models?Journal of Oncology Practice.  14:e375-e383. 2018
    2018 Lay Patient Navigators' Perspectives of Barriers, Facilitators and Training Needs in Initiating Advance Care Planning Conversations With Older Patients With Cancer.Journal of Palliative Care.  33:70-78. 2018
    2018 End-of-Life Care Options and Decision Making for Older Patients With Malignant Brain Tumors-Reply.JAMA Oncology2018
    2018 Participation and interest in support services among family caregivers of older adults with cancer.PSYCHO-ONCOLOGY.  27:969-976. 2018
    2018 Most impactful factors on the health-related quality of life of a geriatric population with cancer.Cancer.  124:596-605. 2018
    2018 Radiation therapy utilization in Medicare beneficiaries with early-stage breast cancer.Cancer.  124:475-481. 2018
    2018 What Is the Role of Symptom Management and Patient-Reported Outcomes in Adherence to Aromatase Inhibitors?Journal of Clinical Oncology.  36:308-309. 2018
    2018 Improving shared decision-making in chronic lymphocytic leukemia through multidisciplinary education.Translational Behavioral Medicine.  8:175-182. 2018
    2017 Choosing Wisely in Oncology: Are We Ready For Value-Based Care?Journal of Oncology Practice.  13:e935-e943. 2017
    2017 Hospital-Based End-of-Life Care and Costs for Older Patients With Malignant Brain Tumors.JAMA Oncology.  3:1581-1582. 2017
    2017 Healthcare utilization, Medicare spending, and sources of patient distress identified during implementation of a lay navigation program for older patients with breast cancer.Breast Cancer Research and Treatment.  167:215-223. 2017
    2017 Feasibility of a Telehealth Educational Program on Self-Management of Pain and Fatigue in Adult Cancer Patients.Journal of Pain and Symptom Management.  53:1071-1078. 2017
    2017 Resource Use and Medicare Costs During Lay Navigation for Geriatric Patients With Cancer.JAMA Oncology.  3:817-825. 2017
    2017 The self-care practices of family caregivers of persons with poor prognosis cancer: differences by varying levels of caregiver well-being and preparedness.Supportive Care in Cancer.  25:2437-2444. 2017
    2017 Establishing a Core Set of Performance Measures to Improve Value in Cancer Care: ASCO Consensus Conference Recommendation Report.Journal of Oncology Practice.  13:135-140. 2017
    2017 Implementation and Impact of Patient Lay Navigator-Led Advance Care Planning Conversations.Journal of Pain and Symptom Management.  53:682-692. 2017
    2016 Choosing Wisely: Opportunities for Improving Value in Cancer Care Delivery?Journal of Oncology Practice.  13:e11-e21. 2016
    2016 Patient-centered support in the survivorship care transition: Outcomes from the Patient-Owned Survivorship Care Plan Intervention.Cancer.  122:3232-3242. 2016
    2016 Adherence to the Choosing Wisely Campaign Recommendations for Radiation Treatment Duration in Breast Cancer: Analysis of Medicare Data at 12 Centers in the Southeastern United States.International Journal of Radiation Oncology - Biology - Physics.  96:E5. 2016
    2016 Intensity Modulated Radiation Therapy in Breast Cancer: Analysis of Medicare Data at 12 Institutions.International Journal of Radiation Oncology - Biology - Physics.  96:E6. 2016
    2016 Treatment Summaries and Follow-Up Care Instructions for Cancer Survivors: Improving Survivor Self-Efficacy and Health Care Utilization.Oncologist.  21:817-824. 2016
    2016 The Patient Care Connect Program: Transforming Health Care Through Lay Navigation.Journal of Oncology Practice.  12:e633-e642. 2016
    2016 Integrating palliative care into the oncology clinic: A joint management approach.Palliative Medicine.  30:510-512. 2016
    2016 Guiding Lay Navigation in Geriatric Patients With Cancer Using a Distress Assessment Tool.Journal of the National Comprehensive Cancer Network.  14:407-414. 2016
    2015 A Quantitative Study of Triggered Palliative Care Consultation for Hospitalized Patients With Advanced Cancer.Journal of Pain and Symptom Management.  50:462-469. 2015
    2014 Guiding lay navigation using the distress thermometer.Journal of Clinical Oncology.  32:195. 2014
    2014 Development and evaluation of a survey to assess survivor knowledge change after survivorship care plans: WiSDOM-B (Wisconsin Survey of cancer DiagnOsis and Management in Breast cancer).Journal of Cancer Education.  29:270-277. 2014
    2014 Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles.Science Translational Medicine.  6:229ra43. 2014
    2014 Update on adjuvant chemotherapy for early breast cancer.Breast Cancer : Basic and Clinical Research.  8:125-133. 2014
    2013 Reply to A. Azad et al.Journal of Oncology Practice.  9:e273. 2013
    2013 Palliative care reduces morbidity and mortality in cancer.Nature Reviews Clinical Oncology.  10:80-89. 2013
    2013 Inpatient hospitalization of oncology patients: are we missing an opportunity for end-of-life care?Journal of Oncology Practice.  9:51-54. 2013
    2012 Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.Breast Cancer Research and Treatment.  131:713-721. 2012
    2011 miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy.Blood.  118:1034-1040. 2011
    2011 The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation.Blood.  117:3391-3401. 2011

    Research Overview

  • Shared decision making, value, Metastatic breast cancer, Supportive care, Payment reform
  • Investigator On

  • UAB17127:A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2–/FGFR-amplified metastatic breast cancer (MBC)  awarded by VANDERBILT UNIVERSITY 2018 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018 - 2023
  • Private Grant  awarded by Genentech 2018 - 2023
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS 2018 - 2023
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2016 - 2022
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS 2016 - 2021
  • Private Grant  awarded by TESARO, INC. 2016 - 2021
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2021
  • Private Grant  awarded by EMD SERONO 2016 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2021
  • UAB 1643- A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer  awarded by Columbia University 2016 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker  awarded by Johns Hopkins University 2014 - 2019
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2019
  • CITY Health II - The Center for the Study of Community Health  awarded by National Center for Chronic Disease Prevention & Health Promo./CDC/DHHS 2014 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2019
  • UAB 1326: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-Amplified but HER2 Mutant Breast Cancer  awarded by Washington University 2013 - 2019
  • UAB 1761: A Randomized, Placebo-Controlled, Double-Blind, Phase II trial of Nanoparticle Albumin-Bound Paclilaxel (Nab-Paclilaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple Negative Breast Cancer.  awarded by University of Chicago 2017 - 2019
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2019
  • Utilizing Multiomic Advanced Diagnostics to Identify Palbociclib Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer  awarded by THE SIDE-OUT FOUNDATION 2017 - 2019
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC. 2017 - 2019
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC. 2014 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2019
  • Private Grant  awarded by PHARMACYCLICS, INC. 2015 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • TBCRC 037 UAB 1644:A Trial of Endocrine Response In Women with Invasive Lobular Breast Cancer.  awarded by University of Pittsburgh 2016 - 2018
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2018
  • Private Grant  awarded by Novartis Pharma AG 2014 - 2017
  • Private Grant  awarded by INCYTE CORPORATION 2014 - 2016
  • Private Grant  awarded by ONCOTHYREON, INC. 2015 - 2016
  • Private Grant  awarded by ARQULE 2014 - 2016
  • Health Care Innovation Challenge  awarded by Centers for Medicare and Medicaid Services/DHHS 2012 - 2015
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015
  • Education And Training

    Full Name

  • Gabrielle Rocque
  • Blazerid

  • grocque